title: Effect of enalapril in dogs with pacing-induced heart failure.
abstract: A repeated-measures study was conducted on 5 dogs to clinically, radiographically, and echocardiographically characterize the actions of the angiotensin-converting enzyme inhibitor, enalapril, before and after development of experimentally induced heart failure. Heart failure was artificially induced, using a surgically implanted programmable ventricular pacemaker, which stimulated the heart at a rate of 245 beats/min until a low-output cardiomyopathic state developed. This condition was then stabilized by decreasing the pacing rate to 190 beats/min. Pacing-induced heart failure was successfully induced in a mean +/- SD 4.2 +/- 1.95 weeks. The condition closely resembled the clinical, radiographic, and echocardiographic features of naturally acquired idiopathic dilated cardiomyopathy in dogs. Enalapril was well tolerated by dogs, and clinical adverse reactions did not develop. Results of echocardiographic studies indicated that enalapril treatment during the control period resulted in a significant (P < 0.05) increase in velocity of circumferential fiber shortening and a significant (P < 0.05) decrease in left ventricular ejection time. Therapeutic responses to enalapril were evident after development of heart failure. These included reduced severity of clinical signs of disease, evidence of decreased radiographically determined cardiac size (2 of 5 dogs), radiographic evidence of a reduction in pulmonary edema and congestion (4 of 5 dogs), significant (P < 0.05) reductions in left atrial and ventricular chamber dimensions (left atrial dimension, diastolic left ventricular internal dimension as determined echocardiographically), and improvement in some echocardiographic indices of left ventricular performance (velocity of circumferential fiber shortening and left ventricular ejection time).
authors.affiliation: Department of Pharmacology, University of Sydney, NSW, Australia.
authors.forename: M S
authors.initials: MS
authors.lastname: Allworth
authors.forename: D B
authors.initials: DB
authors.lastname: Church
authors.forename: J E
authors.initials: JE
authors.lastname: Maddison
authors.forename: R
authors.initials: R
authors.lastname: Einstein
authors.forename: P
authors.initials: P
authors.lastname: Brennan
authors.forename: N
authors.initials: N
authors.lastname: Abdul Hussein
authors.forename: R
authors.initials: R
authors.lastname: Matthews
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002304:Cardiac Pacing, Artificial; D004283:Dog Diseases / Q000175:diagnosis / Q000188:drug therapy*; D004285:Dogs; D004452:Echocardiography / Q000662:veterinary; D004656:Enalapril / Q000627:therapeutic use*; D005260:Female; D006333:Heart Failure / Q000175:diagnosis / Q000188:drug therapy / Q000662:veterinary*; D008297:Male; D011859:Radiography / Q000662:veterinary
chemical_list: D004656:Enalapril